Evidence map›Paper›PMID 34831219›Full record

ArticleCells2021

Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers.

Mi-Hyeon You, Woo Kyung Lee, Meihua Jin, Dong Eun Song, Sheue-Yann Cheng, Tae Yong Kim, Won Bae Kim, Min Ji Jeon, Won Gu Kim

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mi-Hyeon YouDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Woo Kyung LeeLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-6737-3173
Meihua JinDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.ORCID 0000-0003-0196-631X
Dong Eun SongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Sheue-Yann ChengLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Tae Yong KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Won Bae KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Min Ji JeonDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Won Gu KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.ORCID 0000-0002-8404-7759
Ulsan College · KRNational Institutes of Health · US

Funding

the National Research Foundation of Korea (NRF) funded by the Ministry of Education 2020R1F1A1049312 and 2020R1I1A1A01063399
6 · The paper itself

Abstract

The activation of metastatic reprogramming is vital for cancer metastasis, but little is known about its mechanism. This study investigated the potential role of death-associated protein kinase 1 (DAPK1) in thyroid cancer progression. We generated knockdown (KD) DAPK1 using siRNA or shRNA in 8505C and KTC-1 cell lines, which we transiently or stably overexpressed in MDA-T32 and BCPAP cell lines. DAPK1 KD in 8505C and KTC-1 cells significantly increased cell proliferation and colony formation compared with controls. We observed significant inhibition of cancer cell invasion in cells overexpressing DAPK1, but the opposite effect in KD cells. Tumorsphere formation significantly increased after inhibition of DAPK1 expression in 8505C cells and was significantly suppressed in DAPK1-overexpressing MDA-T32 and BCPAP cells. DAPK1 overexpression inhibited mRNA and protein levels of stem markers (OCT4, Sox2, KLF4, and Nanog). Furthermore, the expression of these markers increased after KD of DAPK1 in 8505C cells. Mechanistic studies suggest that DAPK1 may modulate the expression of stem cell markers through the inhibition of β-catenin pathways. These findings were consistent with the public data and our thyroid tissue analysis, which showed higher DAPK1 expression was associated with advanced-stage papillary thyroid cancer with a higher stemness index and lower disease-free survival.

Indexed as

Disease Progressionbeta CateninBiomarkers, TumorCell Line, TumorCell MovementDeath-Associated Protein KinasesGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessNeoplastic Stem CellsRNA, MessengerThyroid Cancer, PapillaryThyroid NeoplasmsTreatment Outcomebeta CateninBiomarkers, TumorDeath-Associated Protein KinasesRNA, MessengerDAPK1neoplastic stem cellsthyroid cancertumor suppressor

Identifiers

PMID34831219
PMCPMC8616132
OpenAlexW3208077821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.